Etanercept: An overview.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12894133.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Medical subject headings
- Arthritis, Psoriatic
- Immunoglobulin G
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha